Increased cannabis use has brought about a sea change in policy and attitudes toward regulation, and a multitude of rules that vary widely between states. The disparity has stymied any effective response to the problems surrounding access to cannabis products for those in need. Health care providers and practitioners, as well as P&T committees, must carefully undertake decisions on rational drug use, whether or not their patients are using cannabis while under their care.
Keywords: 2018 Farm Bill (FB); Board of Pharmacy (BOP); Controlled Substance Act (CSA); Controlled Substance Schedule I (CI); Prescription Drug Monitoring Program (PDMP); cannabidiol (CBD); tetrahydrocannabinol (THC).